KR102367760B1 - 항-포스포리파아제 d4 항체를 포함하는 의약 - Google Patents

항-포스포리파아제 d4 항체를 포함하는 의약 Download PDF

Info

Publication number
KR102367760B1
KR102367760B1 KR1020167002746A KR20167002746A KR102367760B1 KR 102367760 B1 KR102367760 B1 KR 102367760B1 KR 1020167002746 A KR1020167002746 A KR 1020167002746A KR 20167002746 A KR20167002746 A KR 20167002746A KR 102367760 B1 KR102367760 B1 KR 102367760B1
Authority
KR
South Korea
Prior art keywords
seq
sequence
variable region
ser
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167002746A
Other languages
English (en)
Korean (ko)
Other versions
KR20160034934A (ko
Inventor
도모히데 야마자키
마유키 엔도
고지 이시다
Original Assignee
에스비아이 바이오테크 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에스비아이 바이오테크 가부시키가이샤 filed Critical 에스비아이 바이오테크 가부시키가이샤
Publication of KR20160034934A publication Critical patent/KR20160034934A/ko
Application granted granted Critical
Publication of KR102367760B1 publication Critical patent/KR102367760B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020167002746A 2013-07-30 2014-07-30 항-포스포리파아제 d4 항체를 포함하는 의약 Active KR102367760B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2013-158258 2013-07-30
JP2013158258 2013-07-30
PCT/JP2014/070661 WO2015016386A1 (en) 2013-07-30 2014-07-30 Medicament comprising anti-phospholipase d4 antibody

Publications (2)

Publication Number Publication Date
KR20160034934A KR20160034934A (ko) 2016-03-30
KR102367760B1 true KR102367760B1 (ko) 2022-02-24

Family

ID=51493000

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167002746A Active KR102367760B1 (ko) 2013-07-30 2014-07-30 항-포스포리파아제 d4 항체를 포함하는 의약

Country Status (17)

Country Link
US (2) US20160168266A1 (https=)
EP (1) EP3027656B1 (https=)
JP (3) JP6431523B2 (https=)
KR (1) KR102367760B1 (https=)
CN (1) CN105745226B (https=)
AU (1) AU2014297217B2 (https=)
BR (1) BR112016002001B1 (https=)
CA (1) CA2919736C (https=)
DK (1) DK3027656T3 (https=)
ES (1) ES2736324T3 (https=)
HU (1) HUE044469T2 (https=)
MX (1) MX381725B (https=)
PL (1) PL3027656T3 (https=)
RU (1) RU2709741C2 (https=)
SG (2) SG10201800592SA (https=)
TR (1) TR201910330T4 (https=)
WO (1) WO2015016386A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
EP3431504B1 (en) * 2012-01-31 2021-03-24 SBI Biotech Co., Ltd. Anti-phospholipase d4 antibody
MX381725B (es) * 2013-07-30 2025-03-13 Sbi Biotech Co Ltd Medicamento que comprende anticuerpo anti-fosfolipasa d4.
MA45674A (fr) 2016-07-15 2019-05-22 Takeda Pharmaceuticals Co Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes
KR20210006321A (ko) 2018-01-12 2021-01-18 다케다 야쿠힌 고교 가부시키가이샤 항-cd38 항체의 피하 투여
JP7140367B2 (ja) * 2018-05-31 2022-09-21 国立大学法人 東京大学 ヒト由来サンプルにおける可溶型ｔｌｒ７の分析

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102098413B1 (ko) * 2012-01-31 2020-04-07 에스비아이 바이오테크 가부시키가이샤 항-포스포리파아제 ｄ4 항체

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD1367C2 (ro) * 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
AU5784799A (en) * 1998-08-24 2000-03-14 Alphagene, Inc. Secreted proteins and polynucleotides encoding them
US20020146686A1 (en) * 2000-12-07 2002-10-10 Millennium Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of viral disease using 55092
JP2013052781A (ja) 2011-09-05 2013-03-21 Tokai Rika Co Ltd 車両用ミラー装置
MX381725B (es) * 2013-07-30 2025-03-13 Sbi Biotech Co Ltd Medicamento que comprende anticuerpo anti-fosfolipasa d4.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102098413B1 (ko) * 2012-01-31 2020-04-07 에스비아이 바이오테크 가부시키가이샤 항-포스포리파아제 ｄ4 항체

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Immunology, 2(3), pp.169-179(1996)
PLOS ONE, 5(11), p.e13932(2011)
PLOS ONE, 6(11), p.e27544(2011)

Also Published As

Publication number Publication date
DK3027656T3 (da) 2019-08-05
CN105745226B (zh) 2020-03-06
CN105745226A (zh) 2016-07-06
EP3027656B1 (en) 2019-06-26
RU2016106708A (ru) 2017-09-01
US20210130493A1 (en) 2021-05-06
JP2019214621A (ja) 2019-12-19
JP2016534022A (ja) 2016-11-04
AU2014297217B2 (en) 2020-01-16
MX2016001193A (es) 2016-05-26
SG10201800592SA (en) 2018-03-28
EP3027656A1 (en) 2016-06-08
BR112016002001B1 (pt) 2023-04-25
AU2014297217A1 (en) 2016-02-18
RU2016106708A3 (https=) 2018-03-30
SG11201600666SA (en) 2016-02-26
JP6431523B2 (ja) 2018-11-28
ES2736324T3 (es) 2019-12-27
JP6843449B2 (ja) 2021-03-17
WO2015016386A1 (en) 2015-02-05
JP2019014759A (ja) 2019-01-31
CA2919736A1 (en) 2015-02-05
KR20160034934A (ko) 2016-03-30
MX381725B (es) 2025-03-13
RU2709741C2 (ru) 2019-12-19
US20160168266A1 (en) 2016-06-16
HUE044469T2 (hu) 2019-10-28
PL3027656T3 (pl) 2019-10-31
BR112016002001A2 (pt) 2017-08-29
TR201910330T4 (tr) 2019-07-22
CA2919736C (en) 2022-03-22

Similar Documents

Publication Publication Date Title
CN112442128B (zh) 抗磷脂酶d4抗体
KR102367760B1 (ko) 항-포스포리파아제 d4 항체를 포함하는 의약
CN112533955B (zh) 抗b7-h3抗体
JP2023134490A (ja) リンパ球における阻害経路の中和
KR20210013165A (ko) GUCY2c에 특이적인 항체 및 이의 용도
KR102724790B1 (ko) 항 cd147 항체
RU2724742C2 (ru) Анти-orai1 антитело
KR101950898B1 (ko) 항-robo4 항체
JP2017534661A (ja) がんの治療における使用のための抗−ｃｋ８抗体
JP7824969B2 (ja) 抗ｓ１００ａ４ヒト化抗体、使用及び方法
HK40039509A (en) Anti-phospholipase d4 antibody
HK40039509B (zh) 抗磷脂酶d4抗体
KR20230020521A (ko) 아고니스트 항-cd40 항체
CN107108736B (zh) Trail受体结合剂及其用途
WO2025172588A1 (en) Bispecific constructs directed against fap and ltbr

Legal Events

Date Code Title Description
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4